Prosecution Insights
Last updated: October 25, 2026

Revvity Health Sciences Inc.

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days

Analysis

Revvity Health Sciences Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 3 art units, indicating multiple examination assignments with some unit-level overlap.

SHAFQAT, AMY JEANETTE is the busiest examiner, with 1 pending matter. The examiner distribution favors matter-specific response planning, while the smaller art-unit count supports checking whether related technical issues recur within an assigned unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (25%)
3
Medium (75%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (75%)
Multi-statute (no §101)1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
25% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHAFQAT, AMY JEANETTE 1 51.7% +55.6%
DAUNER, JOSEPH G 1 57.0% +35.3%
HOPPE, EMMA RUTH 1 40.0% +58.3%
BUCHANAN, BAILEY CHEYENNE 1 42.9% +57.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 13d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 13d
18641547 Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra SHAFQAT, AMY JEANETTE —
17688062 UNIVERSAL BLOCKING OLIGONUCLEOTIDES FOR REDUCED OFF-TARGET HYBRIDIZATION IN HYBRIDIZATION CAPTURE METHODS HOPPE, EMMA RUTH —
17556209 DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE —

Top Art Units

Art UnitApps
1682 2
3798 1
1683 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18641547 Systems and Methods for 3D Reconstruction of Anatomical Organs and Inclusions Using Short-Wave Infra SHAFQAT, AMY JEANETTE 3798 §103 Final Rejection — Pending Apr 22, 2024
18208140 METHODS FOR DETECTING MUTATIONS IN TARGET NUCLEIC ACIDS USING DUAL PROBES DAUNER, JOSEPH G 1682 §102§103§112 Non-Final OA 13d Pending Jun 09, 2023
17688062 UNIVERSAL BLOCKING OLIGONUCLEOTIDES FOR REDUCED OFF-TARGET HYBRIDIZATION IN HYBRIDIZATION CAPTURE METHODS HOPPE, EMMA RUTH 1683 §103 Non-Final OA — Pending Mar 07, 2022
17556209 DETECTING A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE 1682 §103 Non-Final OA — Pending Dec 20, 2021

Managing Revvity Health Sciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Revvity Health Sciences Inc. have?

Revvity Health Sciences Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.

Which USPTO examiner handles the most Revvity Health Sciences Inc. applications?

Amy Jeanette Shafqat has the most, with 1 of Revvity Health Sciences Inc.'s pending office actions.

What technology area are Revvity Health Sciences Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month